International Therapeutics, Inc. is a Seattle, WA based company focused on the discovery and development of new therapeutics for HIV-1. ITI has two target-specific programs that represent cutting edge science. These are (1) inhibition of nuclear transport of the HIV genetic material and (2) RNA interference technology to inhibit virus production from infected cells. ITI also has a comprehensive screening program for new synthetic compounds. To accomplish this work, the company has implemented and validated a variety of in vitro experimental systems, based on advances made by ITI to current assays, for evaluating the toxicities and anti-HIV activities of lead compounds.

To further the corporate and scientific goals of the company, ITI has established a number of strategic alliances with academic and industry organizations in the United States, Japan and China.

Back to top